Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kelsey Alvarez"'
Autor:
Abigail Cohen, Heather J Landau, Christina Cho, Emily Patterson, Kristine Naputo, Jessica Magaldi, Tara Doga, Kelsey Alvarez, Farah Gaillard, Elizabeth Giles, Philip Rivera, Charlotte Markson, Danielle Romano, Dana Kramer, Grace Yang, Afshana Hoque, Jessica Goldberg, Mary Elizabeth Davis, Angela Katrichis, Camila Bernal, Miguel-Angel Perales, Anjali Desai, Andrew Epstein, Judith Nelson
Publikováno v:
Transplantation and Cellular Therapy. 29:S80-S81
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1328e4b150790f45a1d57d59703367ce
https://doi.org/10.1016/s2666-6367(23)00167-7
https://doi.org/10.1016/s2666-6367(23)00167-7
Autor:
Martin S. Tallman, Xiaoli Mi, Virginia M. Klimek, Raajit K. Rampal, Omar Abdel-Wahab, Stella V Paffenholz, Stephen S. Chung, Justin Taylor, Filiz Sen, Jae H. Park, Allison Sigler, Alexander V Penson, Kelsey Alvarez, Mithat Gonen, Eytan M. Stein
Publikováno v:
The Lancet Haematology. 7:e566-e574
Summary Background The median overall survival of patients with high-risk myelodysplastic syndromes refractory to hypomethylating agents is less than 6 months. Currently, no standard therapy for such patients exists. Preclinical studies have shown th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e459430220d99abcc1c7dc3bd2e79f5
https://doi.org/10.1016/s2352-3026(20)30209-x
https://doi.org/10.1016/s2352-3026(20)30209-x
Autor:
Bria Taylor, Srdan Verstovsek, Tawni Goodman, Raajit K. Rampal, Sean M. Devlin, Prithviraj Bose, Guillermo Montalban-Bravo, Nicole Ard, Kelsey Alvarez, Amber C. King, Michael J. Mauro, Eytan M. Stein, Naveen Pemmaraju, Tapan M. Kadia
Publikováno v:
Blood. 134:4163-4163
Background: Anemia and thrombocytopenia are common in myelofibrosis (MF), and portend adverse outcomes. Few effective modalities to address these cytopenias exist, particularly thrombocytopenia. Further, although the FDA-approved JAK1/2 inhibitor Rux
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fec5e0dc4edcb80b24b0c289d2b7b3d
https://doi.org/10.1182/blood-2019-127661
https://doi.org/10.1182/blood-2019-127661
Autor:
Tawni Goodman, Prithviraj Bose, Kelly Marek, Sean M. Devlin, Srdan Verstovsek, Nicole Ard, Eytan M. Stein, Michael J. Mauro, Naveen Pemmaraju, Tapan M. Kadia, Kelsey Alvarez, Raajit K. Rampal
Publikováno v:
Blood. 132:354-354
Background: Among the most frequent and challenging hematologic manifestations of myelofibrosis (MF) are anemia and thrombocytopenia, the presence of which portends an adverse outcome. Few effective modalities to address these cytopenias exist, parti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54a7c263c4e6342aabd70e696e71f8bb
https://doi.org/10.1182/blood-2018-99-114125
https://doi.org/10.1182/blood-2018-99-114125
Autor:
Morgan Coleman, Jae H. Park, Justin Taylor, Martin S. Tallman, Stephen S. Chung, Janine D. Pichardo, Kelsey Alvarez, Filiz Sen, Raajit K. Rampal, Virginia M. Klimek, Eytan M. Stein, Omar Abdel-Wahab
Publikováno v:
Blood. 132:233-233
There is no standard therapy for patients with myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMA) and the median overall survival (OS) of HMA-refractory MDS patients with IPSS Intermediate-2/High-risk MDS is ~6 months. Here, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a522545705ec93008572336970a9a5b
https://doi.org/10.1182/blood-2018-99-113840
https://doi.org/10.1182/blood-2018-99-113840